Panoramic: Automotive and Mobility 2025
Pharmaceuticals and Biotechnology
Drug companies face pressure from many directions – from a foreboding regulatory landscape, from competitors with alternative brands or generics, from insurers pushing back on prescription drug costs and reimbursement.
Whether you're a global pharmaceuticals company or a biotechnology startup, accomplishing business goals in such a highly regulated industry requires practical, integrated legal analysis and advice. At the same time, you can find opportunities in maximizing the benefits of statutes that encourage new drug development.
Representative experience
Jazz Pharmaceuticals on the acquisition of Cavion, Inc. a company that creates therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.
Medigene AG in US$1bn+ deal with bluebird bio to establish a strategic T cell receptor alliance in cancer immunotherapy.
Gilead Sciences on the technology license agreement with Xencor, Inc., a company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma, and allergic diseases.
Novartis on its US$665m acquisition of Selexys Pharmaceuticals and with its landmark portfolio transformation transactions with GSK and Eli Lilly.
A leading Japanese innovator pharmaceutical firm in numerous Hatch-Waxman actions in relation to generic versions of its product.
DepoMed in patent suit and IPRs against Endo Pharmaceuticals relating to Opana® ER; PTAB upheld Depomed's patents on controlled release gastric retentive technology.
Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck’s antibiotic drug, Invanz®.
Serving as national product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.
A global pharmaceutical company on multijurisdictional personal injury litigation and coordinating the client's defense in more than 27 countries.
A biotechnology manufacturer in investigation of multiple whistleblower allegations that the company promoted a surgical implant for off-label use.
Conducted internal investigations at global pharmaceutical companies into allegations of money laundering, international corruption, and fraudulent practices related to asset transfers in multiple countries.
Awards and recognitions
Band 1 for Life Sciences
Chambers Global: Multi-Jurisdictional
2025
Band 1 for Life Sciences
Chambers Europe-wide
2025
Band 1 for Life Sciences in Japan
Chambers Asia-Pacific
2025
You may also be interested in...
Hogan Lovells Events
Zurich: Life Sciences and Health Care Horizons 2025
22 October 2025
Hogan Lovells Events
DOJ Restricts Bulk Data Transfers to China and Other Countries of Concern
11 February 2025
Hogan Lovells Events
CLE
07 October 2024
Hogan Lovells Events
Zurich: Life Sciences and Health Care Horizons 2024
18 June 2024
Sponsorships and Speaking Engagements
ASHP Midyear Conference 2023
04 December 2023
Sponsorships and Speaking Engagements
FDLI Introduction to Drug Law and Regulation
16 November 2023
Sponsorships and Speaking Engagements
Medicaid and Government Pricing Congress
18 May 2023
Sponsorships and Speaking Engagements
2023 FDLI Annual Conference
18 May 2023
Hogan Lovells Events
Why IP lawyers should care about the IRA
04 May 2023
Sponsorships and Speaking Engagements
Biotech Showcase and exclusive reception during the J.P. Morgan 41st Annual Healthcare Conference
09 January 2023
Sponsorships and Speaking Engagements
ASHP Midyear Conference
06 December 2022
Webinar
APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 4
16 November 2022
Webinar
APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 3
28 September 2022
Webinar
Unpacking the prescription drug provisions of the Inflation Reduction Act of 2022
20 September 2022
Hogan Lovells Events
APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 2
05 July 2022
Sponsorships and Speaking Engagements
ACI Annual "Big Four" Pharmaceutical Pricing Boot Camp
18 May 2022
Hogan Lovells Events
Zurich: Life Sciences and Health Care Horizons 2025
22 October 2025
Hogan Lovells Events
DOJ Restricts Bulk Data Transfers to China and Other Countries of Concern
11 February 2025
Hogan Lovells Events
CLE
07 October 2024
Hogan Lovells Events
Zurich: Life Sciences and Health Care Horizons 2024
18 June 2024
Sponsorships and Speaking Engagements
ASHP Midyear Conference 2023
04 December 2023
Sponsorships and Speaking Engagements
FDLI Introduction to Drug Law and Regulation
16 November 2023
Sponsorships and Speaking Engagements
2023 FDLI Annual Conference
18 May 2023
Sponsorships and Speaking Engagements
Medicaid and Government Pricing Congress
18 May 2023
Hogan Lovells Events
Why IP lawyers should care about the IRA
04 May 2023
Sponsorships and Speaking Engagements
Biotech Showcase and exclusive reception during the J.P. Morgan 41st Annual Healthcare Conference
09 January 2023
Sponsorships and Speaking Engagements
ASHP Midyear Conference
06 December 2022
Webinar
APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 4
16 November 2022
Webinar
APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 3
28 September 2022
Webinar
Unpacking the prescription drug provisions of the Inflation Reduction Act of 2022
20 September 2022
Hogan Lovells Events
APAC Life Sciences and Health Care Webinar Series - Spotlight on Greater China - Session 2
05 July 2022
Sponsorships and Speaking Engagements
ACI Annual "Big Four" Pharmaceutical Pricing Boot Camp
18 May 2022